Oct 25, 2023 20:43 JST

Source: Eisai

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

TIME’s annual list of THE BEST INVENTIONS features “200 extraordinary innovations changing lives.” To compile the list, TIME solicited nominations from its editors and correspondents around the world, and through an open online application process, paying special attention to growing fields, such as AI, green energy, and sustainability. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. (For more information, please visit http://www.time.com/best-inventions-2023)

LEQEMBI is the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, that acts on the underlying pathology of AD.

AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Based on our corporate concept of "human health care (hhc)," we have taken on the challenge of this difficult issue through our nearly 40 years of drug discovery activities in the field of dementia, while spending time with patients and their families. We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Please see full Prescribing Information, including Boxed WARNING in the United States.

MEDIA CONTACTS:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
February 14 2025 11:09 JST
 
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
February 03 2025 16:23 JST
 
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
January 28 2025 08:46 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
January 22 2025 16:18 JST
 
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
January 15 2025 09:03 JST
 
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
January 07 2025 08:14 JST
 
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
December 23 2024 16:22 JST
 
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
December 11 2024 13:45 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
December 05 2024 10:22 JST
 
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
November 28 2024 15:26 JST
 
More Press release >>

Latest Press Release


More Latest Release >>